IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines?

Zhao, Yue; Wei, Kongyuan; Chi, Hao; Xia, Zhijia; Li, Xiaosong

doi:10.3389/fimmu.2022.1022808

Cited by 43 publications

(43 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune system plays important role in the development of cancers, as well as immunotherapy (42). Notably, metabolic molecules are greatly influencing the immune environment (43) and thus the progression of the disease (44).…”

Section: Discussionmentioning

confidence: 99%

By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

BackgroundLung adenocarcinoma (LUAD) is a heterogeneous disease with a dismal prognosis for advanced tumors. Immune-associated cells in the microenvironment substantially impact LUAD formation and progression, which has gained increased attention in recent decades. Sphingolipids have a profound impact on tumor formation and immune infiltration. However, few researchers have focused on the utilization of sphingolipid variables in the prediction of LUAD prognosis. The goal of this work was to identify the major sphingolipid-related genes (SRGs) in LUAD and develop a valid prognostic model based on SRGs.MethodsThe most significant genes for sphingolipid metabolism (SM) were identified using the AUCell and WGCNA algorithms in conjunction with single-cell and bulk RNA-seq. LASSO and COX regression analysis was used to develop risk models, and patients were divided into high-and low-risk categories. External nine provided cohorts evaluated the correctness of the models. Differences in immune infiltration, mutation landscape, pathway enrichment, immune checkpoint expression, and immunotherapy were also further investigated in distinct subgroups. Finally, cell function assay was used to verify the role of CACYBP in LUAD cells.ResultsA total of 334 genes were selected as being most linked with SM activity for further investigation, and a risk model consisting of 11 genes was established using lasso and cox regression. According to the median risk value, patients were split into high- and low-risk groups, and the high-risk group had a worse prognosis. The low-risk group had more immune cell infiltration and higher expression of immune checkpoints, which illustrated that the low-risk group was more likely to benefit from immunotherapy. It was verified that CACYBP could increase the ability of LUAD cells to proliferate, invade, and migrate.ConclusionThe eleven-gene signature identified in this research may help physicians create individualized care plans for LUAD patients. CACYBP may be a new therapeutic target for patients with advanced LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Recently, there has been renewed interest in immune components due to their application in immunotherapy and their prognostic and therapeutic potential. The immune system plays an important role in the development of cancers and immunotherapy 50 . Notably, metabolic molecules greatly influence the immune environment, thus, the disease progression 51,52 .…”

Section: Discussionmentioning

confidence: 99%

An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer

Zhao

Huang

2023

Sci Rep

View full text Add to dashboard Cite

Bladder cancer (BC) is a representative malignant tumor type, and the significance of N7-methyguanosine (m7G)-related lncRNAs in BC is still unclear. Utilizing m7G-related lncRNAs, we developed a prognostic model to evaluate BC's prognosis and tumor immunity. First, we selected prognostic lncRNAs related to m7G by co-expression analysis and univariate Cox regression and identified two clusters by consensus clustering. The two clusters differed significantly in terms of overall survival, clinicopathological factors, and immune microenvironment. Then, we further constructed a linear stepwise regression signature by multivariate Cox and least absolute shrinkage and selection operator (LASSO) regression analysis. Patients fell into high-risk (HR) and low-risk (LR) groups considering the train group risk score. HR group had worse prognoses when stratified by clinicopathological factors. The receiver operating curve (ROC) suggested that the signature had a better prognostic value. Tumor mutation burden (TMB) showed a negative relevance to the risk score, and patients with low TMB presented a better prognosis. Validation of the signature was carried out with multivariate and univariate Cox regression analysis, nomogram, principal component analysis (PCA), C-Index, and quantitative reverse transcriptase PCR (qRT-PCR). Finally, the gene set enrichment analysis (GSEA) demonstrated the enrichment of tumor-related pathways in HR groups, and single-sample gene set enrichment analysis (ssGSEA) indicated a close association of risk score with tumor immunity. According to the drug sensitivity test, the signature could predict the effects of conventional chemotherapy drugs. In conclusion, our study indicates the close relevance of m7G-related lncRNAs to BC, and the established risk signature can effectively evaluate patient prognosis and tumor immunity and is expected to become a novel prognostic marker for BC patients.

show abstract

“…Exosomes secreted by ovarian cancer can induce T-cell arrest to achieve immune escape from cancer cells ( 121 ). Cytokines are closely associated with tumor progression and immune response ( 122 , 123 ), and there is evidence that IL-6 promotes distant metastasis in ovarian cancer ( 124 ). In other cancers, exosomes have been found to induce IL-6 production in monocytes through a Toll-like receptor (TLR).…”

Section: Roles Of Exosomes In the Tmementioning

confidence: 99%

Exosomes: A potential tool for immunotherapy of ovarian cancer

et al. 2023

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is a malignant tumor of the female reproductive system, with a very poor prognosis and high mortality rates. Chemotherapy and radiotherapy are the most common treatments for ovarian cancer, with unsatisfactory results. Exosomes are a subpopulation of extracellular vesicles, which have a diameter of approximately 30–100 nm and are secreted by many different types of cells in various body fluids. Exosomes are highly stable and are effective carriers of immunotherapeutic drugs. Recent studies have shown that exosomes are involved in various cellular responses in the tumor microenvironment, influencing the development and therapeutic efficacy of ovarian cancer, and exhibiting dual roles in inhibiting and promoting tumor development. Exosomes also contain a variety of genes related to ovarian cancer immunotherapy that could be potential biomarkers for ovarian cancer diagnosis and prognosis. Undoubtedly, exosomes have great therapeutic potential in the field of ovarian cancer immunotherapy. However, translation of this idea to the clinic has not occurred. Therefore, it is important to understand how exosomes could be used in ovarian cancer immunotherapy to regulate tumor progression. In this review, we summarize the biomarkers of exosomes in different body fluids related to immunotherapy in ovarian cancer and the potential mechanisms by which exosomes influence immunotherapeutic response. We also discuss the prospects for clinical application of exosome-based immunotherapy in ovarian cancer.

show abstract

IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines?

Cited by 43 publications

References 105 publications

By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma

By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma

An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer

Exosomes: A potential tool for immunotherapy of ovarian cancer

Contact Info

Product

Resources

About